RU2007118196A - Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке - Google Patents
Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке Download PDFInfo
- Publication number
- RU2007118196A RU2007118196A RU2007118196/15A RU2007118196A RU2007118196A RU 2007118196 A RU2007118196 A RU 2007118196A RU 2007118196/15 A RU2007118196/15 A RU 2007118196/15A RU 2007118196 A RU2007118196 A RU 2007118196A RU 2007118196 A RU2007118196 A RU 2007118196A
- Authority
- RU
- Russia
- Prior art keywords
- testosterone
- vol
- solvent
- less
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Claims (13)
1. Композиция, изготовленная в виде формы для внутримышечной инъекции, содержащая сложный эфир тестостерона, который выбран из группы сложных эфиров, включающей линейные и разветвленные нонканоаты, деканоаты, ундеканоаты и додеканоаты, и
носитель, содержащий касторовое масло в концентрации менее чем 45 об.% и сорастворитель.
2. Композиция по п.1, в которой сложный эфир тестостерона представляет собой ундеканоат тестостерона.
3. Композиция по п.2, в которой ундеканоат тестостерона содержится в дозе 150-500 мг на мл.
4. Композиция по п.1, в которой носитель содержит касторовое масло в концентрации менее 40 об.%
5. Композиция по п.1, в которой сорастворитель содержится в количестве от 55 до 65 об.% носителя.
6. Композиция по п.1, в которой сорастворитель представляет собой бензилбензоат.
7. Применение композиции по любому из пп.1-6 для мужской контрацепции.
8. Применение сложного эфира тестостерона, выбранного из группы сложных эфиров, которая включает линейные и разветвленные нонканоаты, деканоаты, ундеканоаты и додеканоаты, для приготовления лекарственного средства для лечения первичного и вторичного гипогонадизма у особи мужского пола мужской, причем указанное лекарственное средство находится в форме, предназначенной для внутримышечной инъекции, и включает носитель, содержащий касторовое масло в концентрации менее чем 45 об.% и сорастворитель.
9. Применение по п.8, в котором первичный гипогонадизм вызван нарушением тестикулярной функции, выбранной из группы нарушений, обусловленных крипторхидизмом, билатеральным тестикулярным перекрутом, орхитом, орхидэктомией, синдромом Кляйнфелтера, химиотерапией или токсическим повреждением, вызванным алкоголем или тяжелыми металлами.
10. Применение по п.9, в котором вторичный гипогонадизм вызван идиопатическим дефицитом гонадотропин-рилизинг-гормона (ГРГ) или повреждением гипофиза-гипоталамуса, обусловленным опухолями, травмой или облучением.
11. Применение сложного эфира тестостерона, выбранного из группы сложных эфиров, которая включает линейные и разветвленные нонканоаты, деканоаты, ундеканоаты и додеканоаты, для приготовления лекарственного средства для лечения заболеваний и симптомов, связанных с недостаточными уровнями тестостерона у мужчины, который подвергается лечению прогестином или подавляющим гонадотропин агентом, причем лекарственное средство находится в форме, предназначенной для внутримышечной инъекции, и содержит носитель, включающий касторовое масло в концентрации менее чем 45 об.% и сорастворитель.
12. Применение по п.11, в котором указанные недостаточные уровни тестостерона у мужчины характеризуются тем, что концентрация тестостерона в сыворотке составляет менее 10 нмолей/л.
13. Применение по п.12, в котором сложный эфир тестостерона представляет собой ундеканоат тестостерона.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300399 | 2003-03-14 | ||
| DKPA200300399 | 2003-03-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005131724/15A Division RU2354381C2 (ru) | 2003-03-14 | 2004-03-15 | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007118196A true RU2007118196A (ru) | 2008-11-27 |
Family
ID=32748728
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005131724/15A RU2354381C2 (ru) | 2003-03-14 | 2004-03-15 | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке |
| RU2007118196/15A RU2007118196A (ru) | 2003-03-14 | 2007-05-16 | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005131724/15A RU2354381C2 (ru) | 2003-03-14 | 2004-03-15 | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US7718640B2 (ru) |
| EP (2) | EP1457208B9 (ru) |
| JP (1) | JP4680891B2 (ru) |
| KR (2) | KR100882378B1 (ru) |
| CN (2) | CN101884639A (ru) |
| AR (1) | AR043603A1 (ru) |
| AT (1) | ATE336251T1 (ru) |
| AU (1) | AU2004218893B2 (ru) |
| BR (2) | BRPI0400214A8 (ru) |
| CA (1) | CA2518910C (ru) |
| CL (1) | CL2004000527A1 (ru) |
| CO (1) | CO5700724A2 (ru) |
| CR (1) | CR7999A (ru) |
| CY (1) | CY1105794T1 (ru) |
| DE (1) | DE602004001893T2 (ru) |
| DK (1) | DK1457208T3 (ru) |
| EA (1) | EA011568B1 (ru) |
| EC (1) | ECSP056095A (ru) |
| ES (1) | ES2271772T3 (ru) |
| HK (1) | HK1069325A1 (ru) |
| HR (1) | HRP20050781B1 (ru) |
| IL (1) | IL170473A (ru) |
| IS (1) | IS2565B (ru) |
| JO (1) | JO2505B1 (ru) |
| ME (2) | ME00149B (ru) |
| MX (1) | MXPA04002395A (ru) |
| NO (1) | NO335179B1 (ru) |
| NZ (1) | NZ542321A (ru) |
| PE (1) | PE20041065A1 (ru) |
| PL (1) | PL1457208T3 (ru) |
| PT (1) | PT1457208E (ru) |
| RS (1) | RS51537B (ru) |
| RU (2) | RU2354381C2 (ru) |
| SA (1) | SA04250040B1 (ru) |
| SI (1) | SI1457208T1 (ru) |
| TW (1) | TWI345976B (ru) |
| UA (1) | UA82510C2 (ru) |
| UY (1) | UY28231A1 (ru) |
| WO (1) | WO2004080383A2 (ru) |
| ZA (2) | ZA200508313B (ru) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050152858A1 (en) * | 2003-07-11 | 2005-07-14 | Isp Investments Inc. | Solubilizing agents for active or functional organic compounds |
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| BRPI0607549A2 (pt) * | 2005-04-15 | 2009-09-15 | Clarus Therapeutics Inc | sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| AU2014200332B2 (en) * | 2008-04-28 | 2016-10-06 | Diurnal Limited | Lipid composition |
| WO2010094623A1 (en) | 2009-02-18 | 2010-08-26 | Bayer Schering Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| US20130178454A1 (en) * | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| EP4186545A1 (en) * | 2012-04-06 | 2023-05-31 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
| SG11201407349UA (en) * | 2012-05-09 | 2014-12-30 | Univ Western Health Sciences | Proliposomal testosterone formulations |
| US20140171918A1 (en) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men |
| FI3659647T3 (fi) | 2013-02-11 | 2024-03-28 | Antares Pharma Inc | Neula-avusteinen suihkuinjektiolaite, jolla on pienennetty liipaisinvoima |
| TW201521731A (zh) * | 2013-03-15 | 2015-06-16 | 利波辛股份有限公司 | 用於口服之脂平衡的長鏈睪固酮酯 |
| EP3033138A4 (en) * | 2013-08-12 | 2017-03-29 | Nanomedical Systems Inc. | Device and method for sustained release of low water solubility therapeutic agent in solubilizer |
| WO2015158823A1 (de) | 2014-04-16 | 2015-10-22 | Veyx-Pharma Gmbh | Veterinärpharmazeutische zusammensetzung und deren verwendung |
| WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| WO2016033556A1 (en) * | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
| CN105056115A (zh) * | 2015-08-05 | 2015-11-18 | 成都市飞龙水处理技术研究所 | 一种治疗化脓性睾丸炎的内服药物及其制备方法 |
| US20180147215A1 (en) | 2016-11-28 | 2018-05-31 | Lipocine Inc. | Oral testosterone undecanoate therapy |
| US11311554B2 (en) | 2018-04-04 | 2022-04-26 | Slayback Pharma Llc | Pharmaceutical compositions of testosterone |
| KR102051808B1 (ko) | 2018-07-23 | 2019-12-04 | 주식회사 종근당 | 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물 |
| EA202191378A1 (ru) * | 2018-12-14 | 2021-10-04 | Ацерус Биофарма Инк. | Активные сложноэфирные производные тестостерона, их композиции и применения |
| EP4164743A2 (en) * | 2020-06-11 | 2023-04-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3164520A (en) | 1962-10-29 | 1965-01-05 | Olin Mathieson | Injectable steroid compositions containing at least 75% benzyl benzoate |
| DE2548413A1 (de) | 1975-10-27 | 1977-04-28 | Schering Ag | Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion |
| US4181721A (en) | 1975-10-27 | 1980-01-01 | Schering Aktiengesellschaft | Depot preparations in an oily, unsaturated solution for intramuscular injection |
| GB1567515A (en) | 1976-05-28 | 1980-05-14 | Akzo Nv | Esters of testo-sterone and 5 -dihydro-testosterone |
| NL7711916A (nl) | 1977-10-29 | 1979-05-02 | Akzo Nv | Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden. |
| US4242863A (en) * | 1978-03-16 | 1981-01-06 | Caterpillar Tractor Co. | Dual phase fuel vaporizing combustor |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5364632A (en) | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| CN1102095A (zh) | 1993-10-30 | 1995-05-03 | 浙江医科大学 | 长效雄激素类制剂——十一酸睾丸注射液 |
| GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| SE9700642D0 (sv) | 1997-02-24 | 1997-02-24 | Kronvall Stefan Med Ab | Medel och sätt för förebyggande och behandling av det metabola syndromet |
| HU228617B1 (en) * | 1997-12-03 | 2013-04-29 | Merial Llc | Long acting injectable formulations containing hydrogenated castor oil |
| CZ293319B6 (cs) | 1998-06-19 | 2004-04-14 | Akzo Nobel N. V. | Derivát testosteronu a farmaceutický prostředek s jeho obsahem |
| WO1999067270A1 (en) | 1998-06-19 | 1999-12-29 | Akzo Nobel N.V. | Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone) |
| TR200102769T2 (tr) | 1999-04-01 | 2002-05-21 | Akzo Nobel N.V. | Testosteron undekanoat ve hint yağı ihtiva eden formülasyon |
| WO2002015938A2 (en) | 2000-08-23 | 2002-02-28 | Akzo Nobel N.V. | Testosterone ester formulation for human use |
-
2004
- 2004-03-11 JO JO200428A patent/JO2505B1/en active
- 2004-03-12 UY UY28231A patent/UY28231A1/es not_active Application Discontinuation
- 2004-03-12 TW TW093106693A patent/TWI345976B/zh active
- 2004-03-12 US US10/798,780 patent/US7718640B2/en active Active
- 2004-03-12 MX MXPA04002395A patent/MXPA04002395A/es active IP Right Grant
- 2004-03-15 NZ NZ542321A patent/NZ542321A/en unknown
- 2004-03-15 CL CL200400527A patent/CL2004000527A1/es unknown
- 2004-03-15 KR KR1020057017087A patent/KR100882378B1/ko active IP Right Grant
- 2004-03-15 AU AU2004218893A patent/AU2004218893B2/en not_active Expired
- 2004-03-15 SI SI200430105T patent/SI1457208T1/sl unknown
- 2004-03-15 RS YUP-2005/0702A patent/RS51537B/en unknown
- 2004-03-15 AT AT04075804T patent/ATE336251T1/de active
- 2004-03-15 BR BRPI0400214A patent/BRPI0400214A8/pt not_active Application Discontinuation
- 2004-03-15 ME MEP-2008-145A patent/ME00149B/me unknown
- 2004-03-15 AR ARP040100843A patent/AR043603A1/es not_active Application Discontinuation
- 2004-03-15 CN CN2010102249063A patent/CN101884639A/zh active Pending
- 2004-03-15 WO PCT/IB2004/000716 patent/WO2004080383A2/en active Search and Examination
- 2004-03-15 EA EA200501819A patent/EA011568B1/ru unknown
- 2004-03-15 ME MEP-145/08A patent/MEP14508A/xx unknown
- 2004-03-15 EP EP04075804A patent/EP1457208B9/en not_active Expired - Lifetime
- 2004-03-15 PT PT04075804T patent/PT1457208E/pt unknown
- 2004-03-15 PL PL04075804T patent/PL1457208T3/pl unknown
- 2004-03-15 KR KR1020087025443A patent/KR20080096717A/ko not_active Application Discontinuation
- 2004-03-15 UA UAA200509571A patent/UA82510C2/ru unknown
- 2004-03-15 CA CA002518910A patent/CA2518910C/en not_active Expired - Lifetime
- 2004-03-15 JP JP2006506335A patent/JP4680891B2/ja not_active Expired - Lifetime
- 2004-03-15 BR BR122017008910A patent/BR122017008910A8/pt not_active Application Discontinuation
- 2004-03-15 PE PE2004000272A patent/PE20041065A1/es active IP Right Grant
- 2004-03-15 EP EP06016949A patent/EP1743646A3/en not_active Withdrawn
- 2004-03-15 RU RU2005131724/15A patent/RU2354381C2/ru active
- 2004-03-15 ES ES04075804T patent/ES2271772T3/es not_active Expired - Lifetime
- 2004-03-15 CN CN200480006912.4A patent/CN1761469B/zh not_active Expired - Lifetime
- 2004-03-15 DE DE602004001893T patent/DE602004001893T2/de not_active Expired - Lifetime
- 2004-03-15 DK DK04075804T patent/DK1457208T3/da active
- 2004-03-21 SA SA04250040A patent/SA04250040B1/ar unknown
-
2005
- 2005-03-07 HK HK05101921A patent/HK1069325A1/xx not_active IP Right Cessation
- 2005-08-24 IL IL170473A patent/IL170473A/en active IP Right Grant
- 2005-09-06 HR HRP20050781AA patent/HRP20050781B1/hr not_active IP Right Cessation
- 2005-09-20 CR CR7999A patent/CR7999A/es not_active Application Discontinuation
- 2005-10-07 CO CO05102559A patent/CO5700724A2/es not_active Application Discontinuation
- 2005-10-12 IS IS8069A patent/IS2565B/is unknown
- 2005-10-12 EC EC2005006095A patent/ECSP056095A/es unknown
- 2005-10-13 ZA ZA200508313A patent/ZA200508313B/en unknown
- 2005-10-13 NO NO20054711A patent/NO335179B1/no unknown
-
2006
- 2006-11-16 CY CY20061101678T patent/CY1105794T1/el unknown
-
2007
- 2007-01-02 ZA ZA200700046A patent/ZA200700046B/xx unknown
- 2007-05-16 RU RU2007118196/15A patent/RU2007118196A/ru not_active Application Discontinuation
-
2009
- 2009-02-24 US US12/391,655 patent/US8338395B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007118196A (ru) | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке | |
| JP2006520377A5 (ru) | ||
| US10940205B2 (en) | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | |
| JP6258368B2 (ja) | 医薬組成物および関連する送達方法 | |
| KR100802366B1 (ko) | 풀베스트란트 제제 | |
| US20210252021A1 (en) | Formulations of deoxycholic acid and salts thereof | |
| JP2021073187A (ja) | 即効型インスリン組成物 | |
| TWI805558B (zh) | 混合物與配方 | |
| ES2253423T3 (es) | Formulacion de un ester de testosterona para uso humano. | |
| JP2005538093A5 (ru) | ||
| CN113194927A (zh) | 环孢菌素类似物的药物制剂 | |
| US10314880B2 (en) | Composition comprising bortezomib | |
| JP5369389B2 (ja) | 痔疾治療用組成物 | |
| JP5223307B2 (ja) | 坐剤 | |
| JP6765475B2 (ja) | 医薬組成物 | |
| US20220175872A1 (en) | Thermogenic compositions and methods | |
| EP3441073A1 (en) | Medicinal composition | |
| JP5217530B2 (ja) | 坐剤 | |
| WO2023174948A2 (en) | Compositions having improved bioavailability of therapeutics and uses thereof | |
| CN116761607A (zh) | 治疗前列腺癌的方法 | |
| CA2496637C (en) | Treatment of inflammatory conditions of the intestine using high density lipoprotein | |
| Mokshagundam et al. | Does concurrent acute ethanol ingestion during omeprazole therapy affect pituitary gonadal axis in male subjects? | |
| US20030130252A1 (en) | Process for affecting neurologic progression | |
| JP2006522060A5 (ru) | ||
| SA01210722B1 (ar) | تكوين صيدلي يحتوي على فولفسترانت fulvestrant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20081126 |